MX2011002409A - Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno. - Google Patents

Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Info

Publication number
MX2011002409A
MX2011002409A MX2011002409A MX2011002409A MX2011002409A MX 2011002409 A MX2011002409 A MX 2011002409A MX 2011002409 A MX2011002409 A MX 2011002409A MX 2011002409 A MX2011002409 A MX 2011002409A MX 2011002409 A MX2011002409 A MX 2011002409A
Authority
MX
Mexico
Prior art keywords
isocitrate dehydrogenase
genes
genetic alterations
malignant glioma
mutations
Prior art date
Application number
MX2011002409A
Other languages
English (en)
Inventor
Hai Yan
Bert Vogelstein
Kenneth W Kinzler
D Williams Parsons
Xiaosong Zhang
Jimmy Chang-Ho Lin
Rebecca J Leary
Philipp Angenendt
Nickolas Papadopoulos
Victor Velculescu
Giovanni Parmigiani
Rachel Karchin
Sian Jones
Darell Bigner
Chien-Tsun Kuan
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2011002409A publication Critical patent/MX2011002409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se encontraron mutaciones del residuo R132 de isocitrato-deshidrogenasa 1 (IDH1) en la mayoría de los astrocitomas Grado II y III y oligodendrogliomas así como en glioblastomas que se desarrollan de estas lesiones de menor grado. Estos tumores sin mutaciones en IDH1 tienen frecuentemente mutaciones en el residuo R172 análogo del gen de IDH2 cercanamente relacionado. Estos hallazgos tienen implicaciones importantes para la patogénesis y diagnosis de gliomas malignos.
MX2011002409A 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno. MX2011002409A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9373908P 2008-09-03 2008-09-03
US11039708P 2008-10-31 2008-10-31
US16273709P 2009-03-24 2009-03-24
PCT/US2009/055803 WO2010028099A1 (en) 2008-09-03 2009-09-03 Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

Publications (1)

Publication Number Publication Date
MX2011002409A true MX2011002409A (es) 2011-09-06

Family

ID=41228200

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015015733A MX359574B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
MX2011002409A MX2011002409A (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
MX2012012788A MX343226B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015015733A MX359574B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012012788A MX343226B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Country Status (11)

Country Link
US (7) US8685660B2 (es)
EP (4) EP3266879B1 (es)
JP (3) JP5421374B2 (es)
CN (1) CN102177251B (es)
AU (1) AU2009288004B2 (es)
CA (1) CA2736125C (es)
DK (2) DK2546365T3 (es)
ES (3) ES2609414T3 (es)
MX (3) MX359574B (es)
PL (2) PL2546365T3 (es)
WO (1) WO2010028099A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2546365T3 (en) 2008-09-03 2017-01-16 Univ Johns Hopkins Genetic changes of isocitrate dehydrogenase and other genes in malignant glioma
US20120121515A1 (en) * 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
EP2253716A1 (en) 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
US8642271B2 (en) * 2009-08-27 2014-02-04 Case Western Reserve University Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3064595B1 (en) * 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
EP2330218A1 (en) * 2009-12-07 2011-06-08 Europath Biosciences, S.L. EGFR and PTEN gene alterations predicts survival in patients with brain tumors
CA2805669C (en) * 2010-07-16 2018-08-21 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
CA2814507A1 (en) * 2010-10-15 2012-04-19 The General Hospital Corporation Microvesicle-based assays
WO2012054915A2 (en) * 2010-10-22 2012-04-26 Duke University Homozygous and heterozygous idh1 gene-defective human astrocytoma cell lines
US9074221B2 (en) 2010-10-25 2015-07-07 Duke University Homozygous and heterozygous IDH1 gene-defective cell lines derived from human colorectal cells
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
KR101873543B1 (ko) 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
JP2014522242A (ja) * 2011-06-06 2014-09-04 メルク・シャープ・アンド・ドーム・コーポレーション イソクエン酸デヒドロゲナーゼ（ｉｄｈ１）遺伝子発現のｒｎａ干渉媒介抑制
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
JP6046618B2 (ja) * 2011-06-22 2016-12-21 国立大学法人京都大学 新規抗腫瘍剤及び新規抗腫瘍剤のスクリーニング方法
AU2012284100B2 (en) 2011-07-19 2016-12-15 Duke University Oligodendroglioma driver genes
WO2013039780A2 (en) * 2011-09-12 2013-03-21 Mayo Foundation For Medical Education And Research Idh1 and idh2 mutations in cholangiocarcinoma
BR112014016612A2 (pt) * 2012-01-05 2017-06-27 Deutsches Krebsforsch meios e métodos para tratar ou diagnosticar cânceres positivos para a mutação idh1 r132h
CN115521264A (zh) 2012-01-06 2022-12-27 法国施维雅药厂 治疗活性化合物及其使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN102732633B (zh) * 2012-07-06 2014-02-26 广州好芝生物科技有限公司 人idh基因突变的检测引物和试剂盒
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
ES2701742T3 (es) 2012-10-29 2019-02-25 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
EP2971079A1 (en) * 2013-03-12 2016-01-20 Novartis AG Markers for isocitrate dehydrogenase inhibitors
US20160113911A1 (en) 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN103451314A (zh) * 2013-09-30 2013-12-18 南京艾迪康医学检验所有限公司 检测idh1、idh2基因多态突变位点的引物、方法和试剂盒
EP3099776A4 (en) * 2014-01-28 2017-10-04 Duke University Mutatations define clinical subgroups of gliomas
KR20220070066A (ko) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
EP3186399B1 (en) 2014-08-25 2022-06-22 Duke University Methods for rapid and sensitive detection of hotspot mutations
WO2016106391A1 (en) * 2014-12-22 2016-06-30 The Broad Institute, Inc. Rapid quantitative detection of single nucleotide polymorphisms or somatic variants and methods to identify malignant neoplasms
US20180087114A1 (en) * 2015-03-05 2018-03-29 Trovagene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid
MD3307271T2 (ro) 2015-06-11 2024-01-31 Agios Pharmaceuticals Inc Metode de utilizare a activatorilor de piruvat kinază
EP3322824A4 (en) * 2015-07-14 2019-01-23 The Johns Hopkins University DETECTION OF DNA DERIVED FROM TUMORS IN THE CEPHALORACHIDIAN LIQUID
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
CN105112545A (zh) * 2015-09-23 2015-12-02 北京泛生子生物科技有限公司 检测人类idh1基因突变的方法及其试剂盒
PL3362065T3 (pl) 2015-10-15 2024-09-16 Les Laboratoires Servier Terapia skojarzona zawierająca iwosidenib, cytarabinę i daunorubicynę lub idarubicynę do leczenia ostrej białaczki szpikowej
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
CN105675868A (zh) * 2016-01-15 2016-06-15 江涛 基于idh1-r132h和atrx表达的胶质瘤分型系统
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
CN107556366A (zh) * 2016-06-30 2018-01-09 上海海和药物研究开发有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
CN110191876A (zh) 2016-10-06 2019-08-30 奥巴斯治疗股份有限公司 用于施用依氟鸟氨酸的制剂
CN106957367B (zh) * 2017-03-31 2020-02-21 北京爱仁医疗科技有限公司 抗idh1 r132h抗体及其制备方法和用途
WO2018213296A1 (en) * 2017-05-15 2018-11-22 Fred Hutchinson Cancer Research Center Genetic panel to molecularly classify diffuse gliomas
WO2019068007A1 (en) * 2017-09-28 2019-04-04 Immpact-Bio Ltd. UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
US20210363588A1 (en) * 2018-03-09 2021-11-25 Duke University Addressing Treatments for Glioblastoma
CN108384857A (zh) * 2018-05-04 2018-08-10 良培基因生物科技（武汉）有限公司 ddPCR技术检测IDH1 R132H基因变异的引物、试剂盒及检测方法
CN108315432A (zh) * 2018-05-04 2018-07-24 良培基因生物科技（武汉）有限公司 ddPCR技术检测IDH1 R132C基因变异的引物、试剂盒及检测方法
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
CN108588194A (zh) * 2018-05-28 2018-09-28 北京诺禾致源科技股份有限公司 利用高通量测序数据检测肿瘤突变负荷的方法及装置
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
JOP20210186A1 (ar) 2019-01-10 2023-01-30 Janssen Biotech Inc مستضدات البروستاتا المستحدثة واستخداماتها
KR102203850B1 (ko) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
CN112071365B (zh) * 2020-09-17 2023-09-19 北京理工大学 基于pten基因状态筛选胶质瘤生物标记物的方法
CN114381522B (zh) * 2021-12-30 2023-09-05 南京医科大学 Nup98基因作为胶质瘤干细胞特异性分子标志物和胶质母细胞瘤治疗及预后靶点的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556747A (en) * 1990-07-09 1996-09-17 E. R. Squibb & Sons, Inc. Method for site-directed mutagenesis
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
WO2000052165A2 (en) * 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
CA2477043A1 (en) * 2001-02-27 2002-09-06 Eos Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
JPWO2003082331A1 (ja) * 2002-03-29 2005-07-28 アンジェスＭｇ株式会社 脳疾患および障害を処置および予防するためのデコイ組成物
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
AU2003287564A1 (en) 2002-11-04 2004-06-07 Howard Hughes Medical Institute Methods of detecting colorectal cancer
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
JP2006300758A (ja) * 2005-04-21 2006-11-02 Apro Life Science Institute Inc 内部標準ペプチドを用いて生体由来試料に含まれる標的タンパク質を定量する方法
JP2006325524A (ja) * 2005-05-27 2006-12-07 Institute Of Physical & Chemical Research 神経幹細胞及び脳神経疾患のためのマーカー
WO2008018789A2 (en) * 2006-08-08 2008-02-14 Leiden University Medical Center Methods and means for diagnosing and treatment of osteoarthritis
US20080108061A1 (en) * 2006-11-02 2008-05-08 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
DK2546365T3 (en) 2008-09-03 2017-01-16 Univ Johns Hopkins Genetic changes of isocitrate dehydrogenase and other genes in malignant glioma
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
EP2253716A1 (en) * 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor

Also Published As

Publication number Publication date
CN102177251B (zh) 2017-06-16
ES2608310T3 (es) 2017-04-07
US20170081730A1 (en) 2017-03-23
US10837064B2 (en) 2020-11-17
CA2736125A1 (en) 2010-03-11
EP2607498B1 (en) 2017-05-03
PL2546365T3 (pl) 2017-07-31
WO2010028099A1 (en) 2010-03-11
DK2326735T3 (en) 2017-01-16
JP6016755B2 (ja) 2016-10-26
JP2014110786A (ja) 2014-06-19
EP2326735B1 (en) 2016-11-16
CA2736125C (en) 2019-04-09
JP5421374B2 (ja) 2014-02-19
AU2009288004B2 (en) 2015-02-05
ES2755139T3 (es) 2020-04-21
US20180282821A1 (en) 2018-10-04
JP2016129517A (ja) 2016-07-21
US20140187764A1 (en) 2014-07-03
CN102177251A (zh) 2011-09-07
US20120202207A1 (en) 2012-08-09
EP3266879A1 (en) 2018-01-10
US9353418B2 (en) 2016-05-31
EP2326735A1 (en) 2011-06-01
US20190106752A1 (en) 2019-04-11
ES2609414T3 (es) 2017-04-20
EP3266879B1 (en) 2019-07-03
US20210317532A1 (en) 2021-10-14
DK2546365T3 (en) 2017-01-16
MX359574B (es) 2018-10-03
US10894987B2 (en) 2021-01-19
US10704108B2 (en) 2020-07-07
EP2546365B1 (en) 2016-11-09
AU2009288004A1 (en) 2010-03-11
EP2607498A1 (en) 2013-06-26
MX343226B (es) 2016-10-28
PL2326735T3 (pl) 2017-04-28
US20110229479A1 (en) 2011-09-22
JP2012501652A (ja) 2012-01-26
EP2546365A1 (en) 2013-01-16
US8685660B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
MX343226B (es) Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
Shoshan et al. NFAT1 directly regulates IL8 and MMP3 to promote melanoma tumor growth and metastasis
Kuhn et al. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Italiano et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas
Kwon et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
Oberholzer et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
EP2837697A3 (en) Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alternations
Prior et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor
Attar et al. Castration-resistant prostate cancer: locking up the molecular escape routes
Cankovic et al. The role of MGMT testing in clinical practice: a report of the association for molecular pathology
Piekielko-Witkowska et al. Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors
Jhaveri et al. Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation
WO2007112330A8 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
EP2518509A3 (en) Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP.
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
Kazmi et al. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer
Panero et al. Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression
Zhang et al. Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia
Hartmann et al. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal‐binding proteins and show a bi‐activated phenotype
Lingohr et al. Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas
Martin et al. Immunologic biomarkers and biomarkers for immunotherapies in gastrointestinal cancer
Verim et al. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels
WO2011093606A3 (ko) Pna 기반의 실시간 pcr 클램핑을 이용한 braf 돌연변이 검출 방법 및 키트
Bluemn et al. Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls
Fujiya et al. ALK inhibition for the treatment of refractory epithelioid inflammatory myofibroblastic sarcoma

Legal Events

Date Code Title Description
FG Grant or registration